Buprenorphine is an opioid that is utilized in the treatment of acute pain management as well as chronic pain management for patients who are undergoing treatment for life-threatening disorders such as cancer, multiple sclerosis, or other conditions. In addition, the increasing frequency of cancer is anticipated to fuel consumer demand for cancer treatments, which in turn is anticipated to support the expansion of the market. A factsheet published by Cancer Research UK estimates that about 17 million people were given a cancer diagnosis in 2018.In addition, the rising prevalence of multiple sclerosis is anticipated to be a driving force behind expansion in the global buprenorphine market throughout the duration of the forecast. The Multiple Sclerosis Trust estimates that there are around 2,500,000 new instances of multiple sclerosis being diagnosed every year across the world.
The global Buprenorphine Market is estimated to be valued at US$ 3,681.9 million in 2020 and is expected to exhibit a CAGR of 14.5% during the forecast period (2020-2027).
Major Players in the Buprenorphine Industry:
1. Siegfried,
Siegfried was founded in 2010 and it’s Zofingen, Switzerland. The company operates in 6 countries.
2. Sanofi
Sanofi founded in 1973, and it’s located in Paris, France. The company operates in 170 Countries.In2020 French drugmaker Sanofi will make 30 of its treatments, including insulin, available on a not-for-profit basis in 40 lower-income countries